Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Medtronic
McKinsey
Express Scripts
Colorcon

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXCARBAZEPINE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Oxcarbazepine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00050934 ↗ Pediatric Epilepsy Study Completed Novartis Pharmaceuticals Phase 3 2002-06-01 This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00050947 ↗ Pediatric Epilepsy Study Completed Novartis Pharmaceuticals Phase 3 2002-07-01 This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00142025 ↗ Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Completed Rea Rehabilitation Centre, Georgia Phase 4 2001-09-01 The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.
NCT00142025 ↗ Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Completed Centre of Chinese Medicine, Georgia Phase 4 2001-09-01 The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxcarbazepine

Condition Name

Condition Name for Oxcarbazepine
Intervention Trials
Epilepsy 13
Seizures 5
Healthy 5
Bipolar Disorder 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxcarbazepine
Intervention Trials
Epilepsy 20
Seizures 13
Epilepsies, Partial 11
Neuralgia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxcarbazepine

Trials by Country

Trials by Country for Oxcarbazepine
Location Trials
United States 138
Japan 34
Mexico 17
Germany 11
Canada 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxcarbazepine
Location Trials
New York 8
Texas 8
Georgia 8
Florida 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxcarbazepine

Clinical Trial Phase

Clinical Trial Phase for Oxcarbazepine
Clinical Trial Phase Trials
Phase 4 21
Phase 3 10
Phase 2/Phase 3 4
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxcarbazepine
Clinical Trial Phase Trials
Completed 46
Terminated 5
Unknown status 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxcarbazepine

Sponsor Name

Sponsor Name for Oxcarbazepine
Sponsor Trials
Novartis 5
Novartis Pharmaceuticals 5
Roxane Laboratories 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxcarbazepine
Sponsor Trials
Other 59
Industry 38
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
McKesson
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.